Galitex is a team of researchers at The Pirbright Institute. Our mission is to develop therapeutic and diagnostic mAbs by leveraging the advantages of the chicken immune system.
Highly conserved mammalian antigens can be poorly immunogenic. Poorly immunogenic targets can fail to yield commercially viable antibodies.
High immunogenicity of mammalian antigens in chickens means that the chicken immune system can raise antibodies to epitopes that are otherwise invisible to the immune systems of mammals. Having access to a greater number and diversity of epitopes means chicken mAbs are better positioned to address diverse commercial needs such as therapeutics that act as agonists or antagonists, or that act in concert with mammalian mAbs, or in diagnostics for detection of molecular markers.
This means chickens can generate an antibody repertoire with expanded epitope coverage relative to mammal repertoires.
Having access to a greater number and diversity of specificities means chicken antibodies are better positioned to address diverse commercial needs such as therapeutics that act as agonists or antagonists of receptors.
Pan-mammalian mAbs
Chicken mAbs can recognise epitopes that are conserved across mammal orthologues. Being able to effectively bind rat, mouse, non-human primate, and human antigens means chicken mAbs can be used in preclinical safety trials that avoid the use of non-human primates.
Epitope accessibility
Chicken mAbs have extended heavy chain CDR3 domains that facilitate improved interactions with therapeutic and diagnostic targets.
The benefits of using Chicken Monoclonal Antibodies
Increased yield of commercially viable antibodies.
Contact us today to learn more about our project and how chicken monoclonal antibodies can be an effective solution for your company.
©2022 Galitex - The Pirbright Institute. All rights reserved. Privacy Policy